TNF and histiocytic sarcoma: In a double-blind, 1:1 randomized, placebo-controlled study involving 20 patients (10 in the placebo arm) with moderate-to-severe HS, refractory (primary or secondary failure) to previous anti-TNF treatment or not eligible to receive adalimumab, HiSCR was achieved, at week 12, in 60% and 10% of MABp1 and placebo groups, respectively.